Thursday, 24 April 2025
  
Login

Australia's most trusted
source of pharma news

Thursday, 24 April 2025
News

Biologics to double COPD market

Posted 23 April 2025 AM

The market for chronic obstructive pulmonary disease (COPD) treatments is expected to grow at an annual compound growth rate of ten per cent until 2033, driven by the launch of biologics and the integration of precision medicine approaches for the condition.

The total revenue across the seven major markets the US, France, Germany, Italy, Spain, the UK, and Japan, is predicted to grow from $18 billion (US$11.6 billion) in 2023 to $46.9 billion (US$30.2 billion) in 2033, according to GlobalData.

To see the whole article, please login

Popular

Biologics to double COPD market
Who's spending the most on HCPs?
Top earning CEO crown goes to...
PBS could become a 'brutal jungle'
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home